Ahmedabad, September 21, 2021: The Philippines has become the first country to grant the emergency permit for use of Sepsivac, developed by Ahmedabad-based Cadila Pharmaceuticals in the treatment of Covid-19.
Looking at its efficacy and safety, the Philippines Food and Drug Administration (FDA) on September 15 granted compassionate special permit for Sepsivac for treatment of Covid-19. The drug was repurposed for COVID 19 and clinical studies are conducted in India with support from Council of Scientific & Industrial Research (CSIR).
“We have approached regulatory agencies of various countries for emergency use permission for Sepsivac, which was found to be effective in dealing with Covid-19 cases in India. Philippines FDA has given compassionate special treatment for restricted use of Sepsivac in Covid-19 treatment, and we have already initiated the supplies,” said Mahidhwaj Sisodia, Executive Vice President, International Formulations Business, Cadila Pharmaceuticals.
“We expect Sepsivac to be part of Covid-19 treatment protocol. Considering the close cooperation among Association of Southeast Asian Nations (ASEAN), we also expect health authorities of other countries to take a similar view, and assist in efforts to tackle the pandemic situation,” he added.
The marketing and formulations teams of Cadila Pharmaceuticals coordinated with authorities in the Philippines. At the same time, key opinion leaders from India shared their clinical experience of Sepsivac with healthcare providers in the Southeast Asian country.
Cadila Pharmaceuticals’ associate Biocare Lifesciences Inc. facilitated interactions with the broader medical fraternity and regulatory agencies in the Philippines in securing the permit. The company will also be handling local activities.
Corporate Comm India (CCI Newswire)
